Kalaris Therapeutics Inc

NASDAQ:KLRS

Biotechnology

Healthcare
$2.30 +3.52%

+$0.16 today

Market cap
$54.75M
Beta
0.14
P/E (TTM)
-2.5
EPS (TTM)
-$1.86
52W Low $2.14High $11.88

Volume 0.07M

Average 0.08M

KLRS Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Kalaris Therapeutics IncNASDAQ: KLRS

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development growth accelerates

Q1 FY2026 research & development of $7.57M rose 25.6% year over year, ahead of the -29.1% change in trailing-twelve-month research & development. Sequentially, it rose 5.8% from the prior quarter. Over 3 fiscal years it compounded at +37.8% a year.

Context

  • Research & development increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +25.6% holds above the trailing-twelve-month pace of -29.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$7.57M+5.8% QoQ
Last fiscal yearDec 2025
$30.75M+149.2% YoY
LTMMar 2026
$32.3M-29.1% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+25.6%——
1 year+149.2%——
3-year CAGR+37.8%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
30.75M USD
Year-over-year change
+149.2%
4-year CAGR
-28.8%

Research & Development vs competitors

How KLRS compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -29.1% is the 6th highest of 9, against a peer median of +7.2%.
  • Over three fiscal years its annual growth of +37.8% compares with a peer median of -5.3%.
KLRS Competitors
Research & Development for KLRS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
STROSutro Biopharma, Inc.LTM Mar 2026$151.37M USD-38.7%+6.7%152.0%
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026$71.8M USD+27.7%+16.5%—
CNTBConnect Biopharma Holdings LimitedFY2025$37.8M USD+29.2%-26.9%59059.4%
STTKShattuck Labs, Inc.LTM Mar 2026$36.3M USD-40.4%-24.8%3629.9%
CNTXContext Therapeutics Inc.LTM Mar 2026$35.41M USD+46.4%+65.0%—
KLRSKalaris Therapeutics IncLTM Mar 2026$32.3M USD-29.1%+37.8%—
IMAImageneBio IncLTM Mar 2026$30.77M USD+23.4%-23.7%—
OVIDOvid Therapeutics Inc.LTM Mar 2026$30.07M USD-8.9%+1.3%422.2%
IFRXInflaRx N.V.LTM Mar 2026€22.87M EUR-34.8%-11.8%77989.1%
Peer median (excluding KLRS) —+7.2%-5.3%3629.9%

Competitors are the stored peer set for KLRS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue1.12M00013K
Gross Profit(1.12M)000(13K)
Gross Margin—————
Research & Development119.62M11.76M11.71M12.34M30.75M
Selling, General & Admin49.08M2.24M1.76M42.92M15.39M
Operating Expenses168.7M14.01M13.46M55.26M46.14M
Depreciation & Amortization1.12M00013K
EBITDA(169.84M)(15.25M)(14.01M)(58.77M)(41.98M)
EBITDA Margin—————
Operating Income(169.82M)(14.01M)(13.46M)(55.26M)(46.15M)
Operating Margin—————
Interest Income1.32M005.49M0
Interest Expense0235K687K01.44M
Other Income / Expenses(1.14M)(1.48M)(1.24M)(3.51M)2.71M
Income Before Tax(170.96M)(15.49M)(14.7M)(58.77M)(43.44M)
Pre-Tax Margin—————
Income Tax Expense1.01M0000
Net Income(171.96M)(15.49M)(14.7M)(58.77M)(43.44M)
Net Margin—————
EPS (Basic)(63.00)(50.62)(42.09)(11.73)(2.85)
EPS (Diluted)(63.00)(50.62)(42.09)(11.73)(2.85)
Weighted Avg Shares2.73M3.33M4.52M5.01M15.27M
Weighted Avg Shares (Diluted)2.73M3.33M4.52M5.01M15.27M

Kalaris Therapeutics Inc

NASDAQ:KLRS

Intrinsic Alpha fair value

Locked

Current Price

$2.30

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.